Innovation is a risky business, yet the Indian ecosystem frequently rewards copying over original thinking. Breaking this cycle requires more than just capital; it requires a leader who refuses to let societal bias or market skepticism define their potential.

In this conversation, we explore the evolution of biotechnology in India. We discuss the biological complexity of protein-based medicines and why the "herd mentality" of the business world makes it difficult for pioneering scientists to scale their ideas into global enterprises.

• The transition from an accidental start in a garage to a global biotech enterprise.
• Navigating the "herd mentality" that prevents original innovation in emerging markets.
• The technical hurdles of producing biosimilars in highly regulated global markets.
• Overcoming gender bias  ...